1.61
+0.06(+3.87%)
Currency In USD
| Previous Close | 1.55 |
| Open | 1.55 |
| Day High | 1.63 |
| Day Low | 1.53 |
| 52-Week High | 5.01 |
| 52-Week Low | 1.41 |
| Volume | 36,787 |
| Average Volume | 51,095 |
| Market Cap | 9.38M |
| PE | -0.7 |
| EPS | -2.3 |
| Moving Average 50 Days | 1.7 |
| Moving Average 200 Days | 2.36 |
| Change | 0.06 |
If you invested $1000 in Aprea Therapeutics, Inc. (APRE) since IPO date, it would be worth $3.93 as of September 08, 2025 at a share price of $1.61. Whereas If you bought $1000 worth of Aprea Therapeutics, Inc. (APRE) shares 5 years ago, it would be worth $3.02 as of September 08, 2025 at a share price of $1.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
GlobeNewswire Inc.
Aug 28, 2025 12:30 PM GMT
DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities wh
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
GlobeNewswire Inc.
Jun 25, 2025 1:00 PM GMT
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early disease control in first HPV+ patie
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
GlobeNewswire Inc.
Mar 31, 2025 12:30 PM GMT
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: